about
Whole-genome sequence of Schistosoma haematobiumProcess of Fragment-Based Lead Discovery-A Perspective from NMRPharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid DehydrogenasesCharting a Path to Success in Virtual ScreeningA Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System TargetsFragment screening and HIV therapeuticsThe ChEMBL bioactivity database: an updateThe Role of Medical Structural Genomics in Discovering New Drugs for Infectious DiseasesDiscovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography †Crystal structure of calf spleen purine nucleoside phosphorylase complexed to a novel purine analogueStructural Studies of Pterin-Based Inhibitors of Dihydropteroate SynthaseDissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein InterfaceDiscovery of Potent Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods and Structure-Based DesignDe Novo Design of Protein Kinase Inhibitors by in Silico Identification of Hinge Region-Binding FragmentsSmall Molecule Regulation of Protein Conformation by Binding in the Flap of HIV ProteaseLigand binding and aggregation of pathogenic SOD1Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitorsDiscovery of a Potent Inhibitor of Replication Protein A Protein–Protein Interactions Using a Fragment-Linking ApproachTargeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B BromodomainIs NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein–Protein Interactions?Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?Natural-product-derived fragments for fragment-based ligand discoveryA Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine KinasesNMR Fragment Screening Hit Induces Plasticity of BRD7/9 BromodomainsFragment Screening of RORγt Using Cocktail Crystallography: Identification of Simultaneous Binding of Multiple FragmentsBioPhytMol: a drug discovery community resource on anti-mycobacterial phytomolecules and plant extractsOpen Drug Discovery Toolkit (ODDT): a new open-source player in the drug discovery fieldStereoselective virtual screening of the ZINC database using atom pair 3D-fingerprintsDiscovery of fragment molecules that bind the human peroxiredoxin 5 active siteVirtual and biophysical screening targeting the γ-tubulin complex--a new target for the inhibition of microtubule nucleationKnowledge-based fragment binding predictionCofactor-independent phosphoglycerate mutase from nematodes has limited druggability, as revealed by two high-throughput screensAutomated NMR fragment based screening identified a novel interface blocker to the LARG/RhoA complexCapturing nature's diversityPredicting Allosteric Effects from Orthosteric Binding in Hsp90-Ligand Interactions: Implications for Fragment-Based Drug DesignACFIS: a web server for fragment-based drug discoveryGentle, fast and effective crystal soaking by acoustic dispensing.Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery
P2860
Q22122084-99A4AC4E-4919-41AB-8137-FEE21E6CFC10Q26738768-1E43D2C2-23A5-41FC-ABEA-298450CEADA8Q26772046-40FF45C3-62FF-4077-80AC-6E8285CE5BF3Q26779035-7D26950E-B3D9-42B9-8B94-D07FB1D36B65Q26781471-99F15F9B-53D3-48DE-9D87-B26594AEB55CQ26826945-53DFFAB5-4A76-45C0-A1E0-C110FD4C5814Q27144224-86FF3861-473A-4B33-B143-06DCDFE52666Q27489856-F55ABFD8-87B8-4374-82B9-BDE0385124AAQ27646546-454CF891-C4CF-481F-8284-FA11A4CDA65CQ27648745-2A11431A-0DAB-4E0F-9D91-400A7A612304Q27658109-9FE13FD8-9E8B-4DD6-9D0F-44BE5AE0613EQ27674729-ADEB5640-B556-4CA8-BECC-8137A898B640Q27675512-0EE2F2A0-ACA4-402F-9937-BCBCA79B0C81Q27677088-B94741E7-6859-43E8-AE59-F2424F9A3E48Q27677124-D10488CE-380D-4EB0-8272-C4E08F688550Q27677527-ECCA65EC-D343-40D8-82B3-58E7758929CDQ27678152-6121E231-7A8B-4700-AF32-FAB579579D68Q27678684-E2713D7A-94DC-4138-B982-5A9583E300F5Q27678993-A3225C2D-B9BE-4F4E-BA66-67A25FFA6F2EQ27680422-C758F376-4AAE-4E42-9407-381EF547F843Q27680754-1C4AC0C5-C307-4CE5-B4E9-51A3B23421A0Q27681373-87D6FF64-0758-4316-934F-0CCF440583A5Q27683344-E2B21BB5-C752-4D5E-8E32-30C2759FFF12Q27683610-F98B4AA7-C6E3-4E40-AA8A-CE110C92CEF8Q27684143-8A99CDC4-E8AA-4DF4-BB42-EACADD9ECC41Q27704896-30D7FA0B-D4F8-46EC-A03C-2C9C0E0062B9Q27720581-4B674496-A38E-4E39-BE34-59AD4D8E35C8Q27902287-F370ACD0-A7D0-42FD-98EB-63A336E9E87AQ27902292-7884A639-399E-44E3-A3BE-A601296FD28DQ27902356-8EAA6090-BC5C-41FA-B75F-B0585F3F6302Q28473225-45636AB4-91A4-44E6-A8F9-A3CDD754CA29Q28488055-1C200548-57E2-49C2-A4A2-8EF83A02B6CCQ28538204-34EEF1A4-80F4-4D7E-99DD-544C72AF9ADFQ28538562-33721C2D-18D2-4F03-84C5-B3FB9589652EQ28539542-90AFDCF9-11DD-4D69-8AF7-19D57F6F38E9Q28546640-82CAC0D0-E95D-4A7A-952D-9CBB6A1B37EFQ28552587-6C01EEA3-F101-499E-9B70-8981465D5B63Q28830078-54CCB9B9-C468-4956-9EE3-BE1D6BE716A1Q30360365-133389D9-86B6-40E7-B80D-46DF2FED7B5CQ30390894-350D3172-FF5C-4FBF-B0E7-398B72B51B36
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A 'rule of three' for fragment-based lead discovery?
@ast
A 'rule of three' for fragment-based lead discovery?
@en
type
label
A 'rule of three' for fragment-based lead discovery?
@ast
A 'rule of three' for fragment-based lead discovery?
@en
prefLabel
A 'rule of three' for fragment-based lead discovery?
@ast
A 'rule of three' for fragment-based lead discovery?
@en
P2093
P1433
P1476
A 'rule of three' for fragment-based lead discovery?
@en
P2093
Chris Murray
Harren Jhoti
Miles Congreve
Robin Carr
P304
P356
10.1016/S1359-6446(03)02831-9
P577
2003-10-01T00:00:00Z